Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High-risk neuroblastoma (HRNB) is a particularly difficult-to-treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolid...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2021-01-01
|
| Series: | Case Reports in Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2021/6610955 |
| _version_ | 1798031584574570496 |
|---|---|
| author | Neofit Spasov Mariya Spasova |
| author_facet | Neofit Spasov Mariya Spasova |
| author_sort | Neofit Spasov |
| collection | DOAJ |
| description | Neuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High-risk neuroblastoma (HRNB) is a particularly difficult-to-treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolidation therapy with high-dose chemotherapy and autologous stem cell transplant, and maintenance therapy with dinutuximab beta. Despite treatment advances, the prognosis of these patients remains poor. As a better response to induction therapy has been associated with prolonged survival in patients with HRNB, we hypothesized that early use of dinutuximab beta—post-induction chemotherapy—may improve patient outcomes. We describe here our experience of administering at least one cycle of dinutuximab beta post-induction and prior to surgery in three children with HRNB who did not demonstrate a complete response to induction chemotherapy. All three patients achieved complete remission. Early use of dinutuximab beta may therefore have the potential to improve outcomes in patients with HRNB. |
| first_indexed | 2024-04-11T19:59:57Z |
| format | Article |
| id | doaj.art-220fcdeca0cf4de08f14e59ac494b7e7 |
| institution | Directory Open Access Journal |
| issn | 2090-6803 2090-6811 |
| language | English |
| last_indexed | 2024-04-11T19:59:57Z |
| publishDate | 2021-01-01 |
| publisher | Hindawi Limited |
| record_format | Article |
| series | Case Reports in Pediatrics |
| spelling | doaj.art-220fcdeca0cf4de08f14e59ac494b7e72022-12-22T04:05:41ZengHindawi LimitedCase Reports in Pediatrics2090-68032090-68112021-01-01202110.1155/2021/66109556610955Early Use of Dinutuximab Beta in Patients with High-Risk NeuroblastomaNeofit Spasov0Mariya Spasova1Medical University Plovdiv, Department of Pediatrics and Medical Genetics, Oncohematology Unit, University Hospital “Sveti Georgi”, Plovdiv, BulgariaMedical University Plovdiv, Department of Pediatrics and Medical Genetics, Oncohematology Unit, University Hospital “Sveti Georgi”, Plovdiv, BulgariaNeuroblastoma is the most common extracranial solid tumor in children, accounting for 15% of all pediatric cancer deaths. High-risk neuroblastoma (HRNB) is a particularly difficult-to-treat form of the disease that requires aggressive multimodality therapy, including induction chemotherapy, consolidation therapy with high-dose chemotherapy and autologous stem cell transplant, and maintenance therapy with dinutuximab beta. Despite treatment advances, the prognosis of these patients remains poor. As a better response to induction therapy has been associated with prolonged survival in patients with HRNB, we hypothesized that early use of dinutuximab beta—post-induction chemotherapy—may improve patient outcomes. We describe here our experience of administering at least one cycle of dinutuximab beta post-induction and prior to surgery in three children with HRNB who did not demonstrate a complete response to induction chemotherapy. All three patients achieved complete remission. Early use of dinutuximab beta may therefore have the potential to improve outcomes in patients with HRNB.http://dx.doi.org/10.1155/2021/6610955 |
| spellingShingle | Neofit Spasov Mariya Spasova Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma Case Reports in Pediatrics |
| title | Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma |
| title_full | Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma |
| title_fullStr | Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma |
| title_full_unstemmed | Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma |
| title_short | Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma |
| title_sort | early use of dinutuximab beta in patients with high risk neuroblastoma |
| url | http://dx.doi.org/10.1155/2021/6610955 |
| work_keys_str_mv | AT neofitspasov earlyuseofdinutuximabbetainpatientswithhighriskneuroblastoma AT mariyaspasova earlyuseofdinutuximabbetainpatientswithhighriskneuroblastoma |